Arrowhead Pharmaceuticals begins Phase 1/2a trial for ARO-CFB, an RNA interference therapeutic targeting complement-mediated kidney disease.
Arrowhead Pharmaceuticals (ARWR) has begun a Phase 1/2a clinical trial for ARO-CFB, an RNA interference therapeutic targeting complement mediated kidney disease. ARO-CFB achieved deep and durable reductions in liver production of complement factor B in preclinical studies. It is Arrowhead's second clinical program addressing diseases linked to complement pathway activation, following ARO-C3 targeting complement component 3.
April 24, 2024
3 Articles